Company profile
Milestone Pharmaceuticals Inc.
NASDAQ:MISTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Etripamil | approved | — | 4 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03464019 | phase3 | terminated | 2018-06-18 | 2023-01-20 | Milestone Pharmaceuticals Inc. | Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). |
| NCT02296190 | phase2 | completed | 2015-03-27 | 2016-12-01 | Milestone Pharmaceuticals Inc. | Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm |
| NCT04952610 | phase3 | completed | 2021-12-13 | 2026-04-10 | Milestone Pharmaceuticals Inc. | Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia |
| NCT04467905 | phase2 | completed | 2020-11-19 | 2023-08-03 | Milestone Pharmaceuticals Inc. | ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2 |
| NCT06716021 | phase3 | not_yet_recruiting | 2027-01-01 | 2029-01-01 | Milestone Pharmaceuticals Inc. | ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 218571 | NDA | MILESTONE PHARMACEUTICALS USA INC | ||||
Loading… | ||||||